Monotherapy with labetalol for hypertensive patients with normal and impaired renal function.
1 Labetalol was given to 41 hypertensive patients in a divided dosage of 150--2,400 mg daily for periods ranging from 1--64 months. 2 Monotherapy with labetalol was adequate in 12 out of 19 patients with essential hypertension and in 15 out of the 22 with renal hypertension. 3 Following a single dose of labetalol 200 mg orally a hypotensive response was seen between 1.5 and 2 hours. 4 In the doses used there was no exercise or postural hypotension. 5 No reduction in overall renal function attributable to labetalol was seen.
D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004983:Ethanolamines / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007674:Kidney Diseases / Q000150:complications*; D007741:Labetalol / Q000009:adverse effects / Q000627:therapeutic use*; D005082:Physical Exertion; D011187:Posture; D011674:Pulse / Q000187:drug effects; D013997:Time Factors
D004983:Ethanolamines; D003404:Creatinine; D007741:Labetalol